Your browser doesn't support javascript.
loading
Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda.
Masiira, Ben; Baisley, Kathy; Mayanja, Billy N; Kazooba, Patrick; Maher, Dermot; Kaleebu, Pontiano.
Afiliação
  • Masiira B; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; ben.masiira@mrcuganda.org.
  • Baisley K; Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
  • Mayanja BN; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
  • Kazooba P; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
  • Maher D; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
  • Kaleebu P; MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Glob Health Action ; 7: 21843, 2014.
Article em En | MEDLINE | ID: mdl-24433941
ABSTRACT

BACKGROUND:

Evidence exists that even at high CD4 counts, mortality among HIV-infected antiretroviral therapy (ART) naïve individuals is higher than that in the general population. However, many developing countries still initiate ART at CD4 ≤350 cells/mm(3).

OBJECTIVE:

To compare mortality among HIV-infected ART naïve individuals with CD4 counts ≥350 cells/mm(3) with mortality in the general Ugandan population and to investigate risk factors for death.

DESIGN:

Population-based prospective HIV cohort.

METHODS:

The study population consisted of HIV-infected people in rural southwest Uganda. Patients were reviewed at the study clinic every 3 months. CD4 cell count was measured every 6 months. Rate ratios were estimated using Poisson regression. Indirect methods were used to calculate standardised mortality ratios (SMRs).

RESULTS:

A total of 374 participants with CD4 ≥350 cells/mm(3) were followed for 1,328 person-years (PY) over which 27 deaths occurred. Mortality rates (MRs) (per 1,000 PY) were 20.34 (95% CI 13.95-29.66) among all participants and 16.43 (10.48-25.75) among participants aged 15-49 years. Mortality was higher in periods during which participants had CD4 350-499 cells/mm(3) than during periods of CD4 ≥500 cells/mm(3) although the difference was not statistically significant [adjusted rate ratio (aRR)=1.52; 95% CI 0.71-3.25]. Compared to the general Ugandan population aged 15-49 years, MRs were 123% higher among participants with CD4 ≥500 cells/mm(3) (SMR 223%, 95% CI 127-393%) and 146% higher among participants with CD4 350-499 cells/mm(3) (246%, 117%-516). After adjusting for current age, mortality was associated with increasing WHO clinical stage (aRR comparing stage 3 or 4 and stage 1 10.18, 95% CI 3.82-27.15) and decreasing body mass index (BMI) (aRR comparing categories ≤17.4 Kg/m(2) and ≥18.5 Kg/m(2) 6.11, 2.30-16.20).

CONCLUSION:

HIV-infected ART naïve individuals with CD4 count ≥350 cells/mm(3) had a higher mortality than the general population. After adjusting for age, the main predictors of mortality were WHO clinical stage and BMI.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Mortalidade / Contagem de Linfócito CD4 / Fármacos Anti-HIV Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Revista: Glob Health Action Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Mortalidade / Contagem de Linfócito CD4 / Fármacos Anti-HIV Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Região como assunto: Africa Idioma: En Revista: Glob Health Action Ano de publicação: 2014 Tipo de documento: Article